Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase

Fig. 5

Co-treatment with VS-5584 and ICG-001 showed superior anti-AML efficacy in vivo in mouse xenograft models. a Mice were treated with vehicle control, VS-5584 5 mg/kg/day, ICG-001 50 mg/kg/day, or combination of two drugs respectively. Survival analysis showed that co-treatment with VS-5584 and ICG-001 significantly prolonged mice life than either of single treatment (p < 0.001). b Analysis of human CD45-positive cells in bone marrow samples harvested from mice at the endpoint of survival analysis by FACS method. Average of bone marrow chimerism was calculated as the average of 7 mice in each group ± SD (two-way ANOVA p = 0.0075)

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us